Sage Journals: Discover world-class research

Abstract

Background:

Preventive medications for dialysis-requiring congestive heart failure (CHF) in non-dialysis Japanese patients with Stage 5 chronic kidney disease (CKD) are unknown. Our aim was to explore which CKD medication was associated with a reduced prevalence of dialysis-requiring CHF in non-dialysis Japanese patients with Stage 5 CKD.

Methods:

The present multicenter, retrospective, cross-sectional study examined the association between CKD medications and the prevalence of dialysis-requiring CHF in non-dialysis Japanese patients with Stage 5 CKD.

Results:

There were 1536 Japanese Stage 5 CKD patients who satisfied our inclusion criteria. We had 309 (20.1%) patients whom had developed dialysis-requiring CHF and 940 patients (60.8%) whom had been using angiotensin-II receptor blockers (ARBs) before initiating dialysis. In our multivariate analysis, only ARB use was significantly associated with a lower risk of CHF (Odds ratio (OR): 0.680, 95% confidence interval (CI): 0.516–0.897; p = 0.0064), of the CKD treatments examined in this study.

Conclusions:

We found that ARB use during the pre-dialysis period is associated with a lower prevalence of CHF in the non-dialysis Japanese patients with Stage 5 CKD, suggesting a possible prevention of dialysis-requiring CHF by ARBs, in non-dialysis Japanese patients with Stage 5 CKD.

Keywords

Angiotensin-II receptor blockers angiotensin-converting enzyme inhibitors chronic kidney disease congestive heart failure dialysis dialysis avoidance Japan preventive medication renal replacement therapy Stage 5

Introduction

The prevalence of chronic kidney disease (CKD) is estimated to be 8–16% worldwide,¹ and the risk of death or cardiovascular events increases with increasing CKD stages.^1–4 In the early-to-moderate CKD stages, inhibition of the renin-angiotensin-aldosterone system has been shown to provide both renal and cardiac protection.^5–10 Angiotensin-converting enzyme inhibitors (ACEIs) are used worldwide to treat hypertension, CKD, and cardiovascular disease.^11–15 A recent meta-analysis has revealed that ACEIs reduce the incidence of all-cause mortality, cardiovascular mortality, and major cardiovascular events, including congestive heart failure (CHF) in early-to-moderate stage CKD and in patients with diabetes mellitus; although angiotensin-II receptor blocker (ARB) use do not reduce the incidence of these events, except for CHF.¹⁶

Hsu et al.²⁶ report that ACEI, but not ARB, used effectively prevent mortality and end-stage renal disease progression, while ARB use only decreases hospitalization due to CHF; however, approximately 5–20% of patients cannot tolerate ACEIs, because of dry cough and the other adverse effects (e.g. angioedema, hypotension, hyperkalemia or renal dysfunction).^17–20 Unfortunately, this persistent dry cough is highly prevalent in the East Asian populations^21,22; therefore, many East Asian patients must be switched from ACEI to ARB, as an alternative treatment. Recently, Nishio et al.²³ reported 2 gene polymorphisms of angiotensin-converting enzyme deletion/insertion (ACE D/I) and bradykinin B2 receptor -58T/C contribute to the risk of ACEI-related cough in East Asians, but a negative association between the ACE I/D polymorphism and ACEI-related cough was observed in Caucasians. Thus, the effect of ARB should be clarified in Japanese CKD patients, which motivated us to explore the effect of ARBs in dialysis-requiring CHF in late-stage CKD patients in Japan.

To date, preventive effects of the medications used for CKD on patients with dialysis-requiring CHF is not well understood.^24–26 In addition, few clinical reports focus on patients with Stage 5 CKD, which is defined by an estimated glomerular filtration rate (eGFR) of < 15 mL/min/1.73m². A recent study reports that ACEI or ARB use in non-dialysis patients with Stage 5 CKD is associated with a reduced risk of long-term dialysis or death,²⁷ but no information was provided regarding dialysis-requiring CHF patients.

Among the uremic symptoms that require renal replacement therapy (RRT), CHF significantly predicts the incidence of cardiac events and mortality in end-stage kidney disease.^28,29 Unfortunately, no effective preventative treatment for CHF has been definitively described for patients with Stage 5 CKD. Furthermore, the ability of ARB to prevent CHF (a major reason for initiating RRT) has not been assessed in patients with Stage 5 CKD. Thus, we evaluated the associations between various medications (including ACEI and ARB) and the prevalence of dialysis-requiring CHF in non-dialysis Japanese patients with Stage 5 CKD. Our objective was to explore which CKD medication would be associated with a reduced prevalence of dialysis-requiring CHF, in non-dialysis Japanese patients with Stage 5 CKD.

Methods

Study design

This study used a cross-sectional, observational multicenter design, and included 3447 Japanese patients across nine Japanese institutions, whom had initiated RRT between 1 January 2006 and 31 October 2013. All participating institutions belonged to the Japanese Study Group for Assessing Initiation of Renal Replacement Therapy (J-START), and these institutions served as the primary pre-dialysis source of information, for patients with end-stage kidney disease. All the J-START members are nephrologists who have been certified by the Japanese Society of Nephrology and the Japanese Society of Dialysis Therapy. We collected clinical information and hematological data at the institutional level, immediately before the patient’s first hemodialysis session, according to the J-START database sheet (Microsoft Excel). Each patient’s information was only labeled with the institution and patient number, to protect their privacy. This study was performed in accordance with the Declaration of Helsinki. The ethics committee for clinical research of Jikei University School of Medicine approved this study (permission number 25-343).

To explore the association between CKD medications and dialysis-requiring CHF, the following inclusion criteria were selected:

Only Japanese Stage 5 CKD patients who were followed up over 3 months and received a stable prescription > 3 months by a nephrologist, to exclude emergent initiation of dialysis, for AKI; and

Those with patient records with complete data, regarding the following factors: age, gender, presence of diabetic kidney disease, reasons (uremic symptoms) for initiating RRT, history of ischemic heart disease (IHD), duration of nephrologist follow-up, systolic and diastolic blood pressure, and laboratory data (hemoglobin, albumin, urea nitrogen, creatinine, sodium, potassium, chloride, corrected calcium, phosphorus, C-reactive protein (CRP) and intact parathyroid hormone (PTH).

As a result, 1911 patients were excluded from the analysis, due to having Stage 1–4 CKD (45 patients), being ⩽ 19 years old (3 patients), having an uncertain history of IHD (164 patients) and comorbidity (29 patients), having a follow-up period of < 3 months or of unknown length (819 patients), lack of data regarding medication use in the previous 3 months (254 patients) and insufficient laboratory data (624 patients). Therefore, among the 3474 patients whom we evaluated, there were 1536 Japanese patients satisfying our inclusion criteria whom were included in our analysis (Figure 1). Compared to the included patients, the excluded patients whom had < 3 months of nephrologist follow-up had a significantly higher prevalence of dialysis-requiring CHF (35.8% versus 20.1%; p < 0.0001), a lower prevalence of diabetic kidney disease (35.9% versus 43.3%; p = 0.0024), a lower frequency of ARB use (36.5% versus 60.8%; p < 0.0001), and higher levels of CRP (3.17 ± 4.96 mg/dL versus 1.27 ± 3.06 mg/dL; p < 0.0001). We observed no significant differences regarding age, gender, eGFR and history of IHD, when the included and excluded patients were compared.

Figure 1.

Study flow chart.

The eGFR was calculated using the new Japanese equations,³⁰ for men (1) and for women (2):

Men : eGFR (mL / \min / 1 . {73 m}^{2}) = 194 \times {Cr}^{- 1.094} \times {age}^{- 0.287}

(1)

Women : eGFR (mL / \min / 1 . {73 m}^{2}) = 194 \times {Cr}^{- 1.094} \times {age}^{- 0.287} (\times 0.739)

(2)

We used a modified version of Framingham heart failure diagnostic criteria to confirm the diagnosis of CHF.³¹ A diagnosis of CHF was made according to the presence of orthopnea, sudden weight gain and radiography findings (enlarged pulmonary vessels, alveolar edema and pleural effusion); and these findings were rapidly resolved after the first hemodialysis session.

We also collected information regarding the patients’ medication use before starting dialysis. The specific medications that we evaluated were erythropoietin receptor stimulating agents (ESAs), ACEIs, ARBs, calcium channel blockers (CCBs), loop diuretics, other anti-hypertensive agents (alpha-blockers and/or beta-blockers, and/or other hypertensive drugs), Vitamin D receptor activators (VDRAs), calcium carbonate (CaCO₃) and AST-120 (Kureha Corporation, Tokyo, Japan) is an orally administered spherical carbon adsorbent that can adsorb various small molecule uremic toxins.³²

Variables

The primary outcome was the prevalence of CHF at dialysis initiation, and the predictor variable was the CKD medications used before dialysis initiation. We also selected the following explanatory variables: gender; age; comorbid diabetes mellitus; medical history of IHD; the nephrology follow-up period; systolic and diastolic blood pressure; use of ARBs, ACEIs, CCBs, other antihypertensive drugs, loop diuretics, ESAs, VDRAs, CaCO₃, or AST-120; eGFR; serum uric acid; serum potassium; serum chloride; serum corrected calcium; serum phosphorus; serum intact PTH; serum albumin; and hemoglobin concentration.

Statistics

Statistical analyses were performed using JMP 9.0 (SAS Institute Inc., Cary, NC, USA). Data were expressed as the mean ± SD or number (percentage) of patients. Comparisons across the various groups were performed using the Pearson chi-squared test for categorical data and the Dunnett test for continuous data. All tests were two-tailed, and a p < 0.05 was considered statistically significant. Factors that were associated with CHF during the univariate analysis were subsequently included in a multivariate model. Multivariate logistic regression analyses were performed to identify the covariates that were associated with the development of dialysis-requiring CHF. Odds ratios (ORs) and 95% CIs were determined using univariate and multivariate logistic regression models for the factors that were significantly associated with CHF. We used Forrest plots to summarize the results of the logistic regression analysis, and Microsoft Excel to plot the 95% CI range on the log scale Forrest plots.

Results

Reasons for starting dialysis

Figure 2 shows the reasons (uremic symptoms) for initiating dialysis. Among the 1536 Japanese patients, 309 patients (20.1%) started RRT due to developing CHF, 230 patients (15.0%) started RRT due to gastro-intestinal symptoms, 198 patients (12.9%) started RRT due to uncontrollable edema, 77 patients (5.0%) started RRT due to other symptoms (anemia, neurological or other symptoms), and 722 patients (47.0%) underwent planned RRT (with no symptoms).

Figure 2.

Reasons (uremic symptoms) for initiating dialysis in Japanese patients with Stage 5 CKD. Data are expressed as the percentage of the total study population.

Comparison of patients presenting with or without CHF

The patients’ characteristics and laboratory test results from immediately before starting dialysis are shown in Table 1, along with a comparison of patients with and without CHF. Compared to the patients without CHF, the patients whom presented with CHF were significantly older (66.7 ± 12.9 years, versus 68.9 ± 13.4 years; p = 0.0092), had a higher frequency of diabetic kidney disease (40.1% versus 55.3%; p < 0.0001), a higher frequency of a medical history of IHD (16.3% versus 28.5%; p < 0.0001), a lower diastolic blood pressure (77.6 ± 13.8 mmHg versus 75.3 ± 16.5 mmHg; p = 0.0123), and a shorter follow-up period (3.83 ± 3.73 years versus 3.14 ± 3.11 years; p = 0.0028).

Table 1.

Baseline characteristics and comparison of patients who presented with or without CHF.

Variables	Overall(n = 1536)	CHF present(n = 309)	CHF absent(n = 1227)	P-value
Male, n (%)	1058 (68.9)	216 (69.9)	842 (68.6)	0.6640
Diabetic kidney disease, n (%)	663 (43.2)	171 (55.3)	492 (40.1)	< 0.0001
History of IHD, n (%)	288 (18.8)	88 (28.5)	200 (16.3)	< 0.0001
Age (years)	67.2 ± 13.0	68.9 ± 13.4	66.7 ± 12.9	0.0092
Systolic BP (mmHg)	152.1 ± 24.9	150.7 ± 27.9	152.4 ± 24.1	0.2576
Diastolic BP (mmHg)	77.2 ± 14.4	75.3 ± 16.5	77.6 ± 13.8	0.0123
Nephrologist follow-up (years)	3.69 ± 3.62	3.14 ± 3.11	3.83 ± 3.73	0.0028
Laboratory data
Hemoglobin (g/dL)	8.77 ± 1.48	8.54 ± 1.51	8.83 ± 1.47	0.0023
CRP (mg/dL)	1.27 ± 3.06	2.60 ± 4.43	0.94 ± 2.50	< 0.0001
Urea nitrogen (mg/dL)	89.3 ± 26.4	88.4 ± 29.2	89.7 ± 25.6	0.4561
Creatinine (mg/dL)	9.36 ± 3.18	8.54 ± 3.06	9.57 ± 3.18	< 0.0001
eGFR (mL/min/1.73m²)	5.20 ± 1.92	5.84 ± 2.32	5.04 ± 1.77	< 0.0001
Uric acid (mg/dL)	8.50 ± 2.23	8.78 ± 2.43	8.43 ± 2.18	0.0122
Sodium (mEq/L)	138.0 ± 4.5	138.2 ± 4.0	138.0 ± 4.6	0.4504
Potassium (mEq/L)	4.60 ± 0.83	4.50 ± 0.86	4.63 ± 0.82	0.0174
Chloride (mEq/L)	105.0 ± 6.0	104.0 ± 6.2	105.2 ± 6.0	0.0018
Corrected calcium (mg/L)	8.54 ± 0.94	8.67 ± 0.97	8.51 ± 0.92	0.0062
Phosphorus (mg/dL)	6.15 ± 1.67	6.14 ± 1.79	6.15 ± 1.64	0.8987
Albumin (g/dL)	3.24 ± 0.59	3.03 ± 0.57	3.30 ± 0.58	< 0.0001
Intact PTH (pg/mL)	322.6 ± 250.4	314.6 ± 232.4	324.6 ± 254.8	0.5342
CTR (%)	54.1 ± 6.5	58.0 ± 6.7	53.2 ± 6.1	< 0.0001
Medications
ESAs, n (%)	1286 (83.7)	252 (81.6)	1034 (84.3)	0.2475
VDRAs, n (%)	392 (25.5)	55 (17.8)	337 (27.5)	0.0005
CaCO₃, n (%)	528 (34.4)	83 (26.9)	445 (36.3)	0.0019
Loop diuretics, n (%)	1071 (69.7)	255 (82.5)	816 (66.5)	< 0.0001
AST-120, n (%)	308 (20.1)	63 (20.4)	245 (20.0)	0.8688
CCBs, n (%)	1166 (75.9)	236 (76.4)	930 (75.8)	0.8310
ARBs, n (%)	936 (60.9)	173 (56.0)	763 (62.2)	0.0460
ACEIs, n (%)	251 (16.3)	42 (13.6)	209 (17.0)	0.1437

Data are expressed as a number (%) of patients or the mean ± SD.

ACEI: angiotensin-converting enzyme inhibitor; BP: blood pressure; ARB: angiotensin-II receptor blocker; AST-120: an orally administered uremic toxins adsorbent³²; CaCO₃: calcium carbonate; CCB: calcium channel blocker; CHF: congestive heart failure; CRP: C-reactive protein; CTR: cardiothoracic ratio; eGFR: estimated glomerular filtration rate; ESA: erythropoietin receptor stimulating agent; IHD: ischemic heart disease; PTH: parathyroid hormone; VDRA: vitamin D receptor activator.

In addition, the patients who presented with CHF used loop diuretics significantly more frequently (66.5% versus 82.5%; p < 0.0001), and used ARBs (62.2% versus 56.0%; p = 0.0460), CaCO₃ (36.3% versus 26.9%; p = 0.0019) and VDRAs (27.5% versus 17.8%; p = 0.0005) less frequently, when compared to the patients without CHF; however, we observed no significant associations between CHF development and the use of ACEIs, CCBs, ESAs, AST-120 or other hypertensive drugs.

The patients who started RRT due to CHF development also had significantly higher levels of CRP (0.94 ± 2.50 mg/dl versus 2.60 ± 4.43 mg/dl; p < 0.0001), eGFR (5.04 ± 1.77 mL/min/1.73m² versus 5.84 ± 2.32 mL/min/1.73m²; p < 0.0001), uric acid (8.43 ± 2.18 g/dL versus 8.78 ± 2.43 g/dL; p = 0.0122), corrected calcium (8.51 ± 0.92 mg/L versus 8.67 ± 0.97 mg/L; p = 0.0062) and cardiothoracic ratio (CTR) (53.2 ± 6.1% versus 58.0 ± 6.7%; p < 0.0001), as well as significantly lower levels of hemoglobin (8.83 ± 1.47 g/dL versus 8.54 ± 1.51g/dL; p = 0.0023), serum creatinine (9.57 ± 3.18 mg/dL versus 8.54 ± 3.06 mg/dL; p < 0.0001), potassium (4.63 ± 0.82 mEq/L versus 4.50 ± 0.86 mEq/L; p = 0.0174), chloride (105.2 ± 6.0 mEq/L versus 104.0 ± 6.2 mEq/L; p = 0.0018) and serum albumin (3.30 ± 0.58 g/dL versus 3.03 ± 0.57 g/dL; p < 0.0001). There were no significant differences between the two groups, regarding gender, systolic blood pressure, urea nitrogen, sodium, phosphorus and intact PTH.

Association between various risk factors and the prevalence of CHF

As is shown in Table 2, univariate and multivariate-adjusted logistic regression analysis were used to assess the independent association between CHF development and medications or the other clinical parameters. The primary outcome was the prevalence of CHF at dialysis initiation, the predictor variable was ARB use, and the covariates were determined according to their univariate relationship or importance within the explanatory variables. In the univariate analysis, older age, shorter nephrologist follow-up, lower diastolic blood pressure, and higher levels of corrected calcium were risk factors for dialysis-requiring CHF, although they were not independent risk factors after the multivariate-adjusted logistic regression analysis. VDRA and CaCO₃ use were also associated with dialysis-requiring CHF in the univariate model, although these associations disappeared after adjusting for intact PTH, corrected calcium and the nephrologist follow-up period.

Table 2.

The association between various risk factors and the prevalence of CHF in non-dialysis Japanese patients with Stage 5 CKD.

Variables	Univariate model		Multivariate model
	OR (95% CI)	P value	OR (95% CI)	P value
Age	1.013 (1.003–1.024)	0.0085	1.007 (0.995–1.020)	0.2381
Diabetic kidney disease	1.851 (1.440–2.383)	< 0.0001	1.539 (1.151–2.062)	0.0036
Nephrologist follow-up	0.941 (0.902–0.978)	0.0017	0.968 (0.927–1.008)	0.1176
History of IHD	2.045 (1.526–2.726)	< 0.0001	1.777 (1.293–2.432)	0.0004
Diastolic BP	0.989 (0.980–0.998)	0.0120	1.003 (0.993–1.013)	0.6055
Laboratory data
Hemoglobin	0.876 (0.803–0.954)	0.0022	0.897 (0.815–0.986)	0.0250
eGFR	1.219 (1.147–1.296)	< 0.0001	1.143 (1.065–1.227)	0.0002
Albumin	0.469 (0.379–0.580)	< 0.0001	0.712 (0.552–0.918)	0.0090
Corrected calcium	1.210 (1.056–1.389)	0.0058	1.070 (0.911–1.259)	0.4081
Intact PTH	0.998 (0.999–1.000)	0.5273	1.000 (0.998–1.001)	0.1768
CRP	1.157 (1.113–1.205)	< 0.0001	1.121 (1.077–1.171)	< 0.0001
Medications
ARBs	0.774 (0.601–0.997)	0.0470	0.680 (0.516–0.897)	0.0064
ACEIs	0.766 (0.530–1.086)	0.1364	0.704 (0.476–1.022)	0.0656
Loop diuretics	2.378 (1.746–3.292)	< 0.0001	1.872 (1.336–2.658)	0.0002
VDRAs	0.572 (0.413–0.780)	0.0003	0.802 (0.561–1.134)	0.2142
CaCO₃	0.645 (0.487–0.848)	0.0016	0.785 (0.574–1.168)	0.1243
ESAs	0.825 (0.599–1.151)	0.2535	0.946 (0.663–1.366)	0.7640
CCBs	1.032 (0.773–1.391)	0.8308	1.095 0.796–1.520)	0.5795
Other hypertension drugs	1.176 (0.916–1.510)	0.2028	1.034 (0.786–1.360)	0.8087
AST-120	1.026 (0.748–1.392)	0.8690	1.256 (0.892–1.753)	0.1894

ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin-II receptor blocker; AST-120: an orally administered uremic toxins adsorbent32; BP: blood pressure; CaCO₃: calcium carbonate; CCB: calcium channel blocker; CHF: congestive heart failure; CKD: chronic kidney disease; CRP: C-reactive protein; eGFR: estimated glomerular filtration rate; ESA: erythropoietin receptor stimulating agent; IHD: ischemic heart disease; PTH: parathyroid hormone; VDRA: vitamin D receptor activator.

The multivariate-adjusted logistic regression analysis revealed that, among all the medications that we examined, only ARB use was independently associated with a significantly reduced risk of dialysis-requiring CHF (OR: 0.680; 95% CI: 0.516–0.897; p = 0.0064). Though ACEI use was not independently associated with dialysis-requiring CHF (OR: 0.704; 95% CI: 0.476–1.022; p = 0.0656), a nonsignificant CHF-preventive tendency was observed. In contrast, no significant reduction in the risk of dialysis-requiring CHF was observed for the use of: VDRA, CaCO₃, ESA, AST-120, CCB or the other hypertensive drugs. A significant positive correlation was also confirmed between CHF development and loop diuretic use (OR: 1.872; 95% CI: 1.336–2.658; p = 0.0002). Comorbid diabetic kidney disease (p = 0.0036), a history of IHD (p = 0.0004), high levels of serum CRP (p < 0.00001) and eGFR (p = 0.0002), low levels of serum albumin (p = 0.0090) and hemoglobin (p = 0.0250) were also independent risk factors for dialysis-requiring CHF.

Comparison of patients’ characteristics between ARB users and non-users

As only ARB was significantly associated with a decreased risk of dialysis-requiring CHF, we compared the characteristics of ARB users (940 patients (60.8%)) with ARB non-users (606 patients (39.2%)), to confirm whether any significant differences existed. As we show in Table 3, compared with non-users of ARB, the ARB users were significantly younger (66.5 ± 12.8 years versus 68.0 ± 12.4 years; p = 0.0243); had a higher frequency of diabetic kidney disease (47.1% versus 36.8%; p < 0.0001); had a shorter nephrologist follow-up period (3.48 ± 3.31 years, versus 4.03 ± 4.04 years; p = 0.0030); and had a higher frequency of CCB use (79.6% versus 70.1%; p < 0.0001), ACEI use (18.2% versus 13.2%; p < 0.0094) and other hypertensive drug use (48.3% versus 41.4%; p < 0.008).

Table 3.

Comparison of patients’ characteristics between ARB users and non-users.^a

Variables	ARB users(n = 936)	ARB non-users(n = 600)	p value
Prevalence of CHF, n (%)	173 (18.5)	136 (22.7)	0.0460
Male, n (%)	659 (70.4)	399 (66.5)	0.1086
Diabetic kidney disease, n (%)	440 (47.0)	223 (37.2)	< .0001
History of IHD, n (%)	180 (19.2)	108 (18.0)	0.5465
Age (years)	66.5 ± 12.7	68.1 ± 13.4	0.0204
Systolic BP (mmHg)	153.6 ± 24.3	149.7 ± 25.7	0.0030
Diastolic BP (mmHg)	77.6 ± 13.9	76.5 ± 15.1	0.1369
Nephrologist follow-up (years)	3.48 ± 3.31	4.02 ± 4.04	0.0030
Laboratory data
Hemoglobin (g/dL)	8.76 ± 1.49	8.79 ± 1.46	0.6901
CRP (mg/dL)	1.21 ± 3.19	1.37 ± 2.86	0.3085
Urea nitrogen (mg/dL)	88.8 ± 27.0	90.4 ± 25.4	0.2586
Creatinine (mg/dL)	9.31 ± 3.07	9.45 ± 3.33	0.3870
eGFR (mL/min/1.73m²)	5.25 ± 1.90	5.13 ± 1.94	0.2225
Uric acid (mg/dL)	8.56 ± 2.24	8.41 ± 2.23	0.1891
Sodium (mEq/L)	138.0 ± 4.0	137.9 ± 5.2	0.6601
Potassium (mEq/L)	4.63 ± 0.79	4.56 ± 0.89	0.1179
Chloride (mEq/L)	105.5 ± 5.8	104.1 ± 6.3	< .0001
Corrected calcium (mg/L)	8.57 ± 0.91	8.50 ± 0.97	0.1637
Phosphorus (mg/dL)	6.14 ± 1.63	6.17 ± 1.72	0.7041
Albumin (g/dL)	3.22 ± 0.58	3.27 ± 0.59	0.1458
Intact-PTH (pg/mL)	313.0 ± 251.2	337.5 ± 248.7	0.0610
CTR (%)	53.8 ± 6.5	54.6 ± 6.5	0.0257
Medications
ESAs, n (%)	791 (84.5)	495 (82.5)	0.2982
VDRAs, n (%)	236 (25.2)	156 (26.0)	0.7302
CaCO₃, n (%)	310 (33.1)	218 (36.3)	0.1957
Loop diuretics, n (%)	662 (70.7)	409 (68.2)	0.2867
AST-120, n (%)	199 (21.3)	109 (18.2)	0.1395
CCBs, n (%)	744 (79.5)	422 (70.3)	< .0001
ACEIs, n (%)	171 (18.3)	80 (13.3)	0.0107
Other hypertension drugs, n (%)	454 (48.3)	251 (41.4)	0.0080

Data are expressed as number (%) of patients or mean ± SD.

ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin-II receptor blocker; BP: blood pressure; CaCO₃: calcium carbonate; CCB: calcium channel blocker; CHF: congestive heart failure; CRP: C-reactive protein; CTR: cardiothoracic ratio; eGFR: estimated glomerular filtration rate; ESA: erythropoietin receptor stimulating agent; IHD: ischemic heart disease; PTH: parathyroid hormone; VDRA: vitamin D receptor activator.

ARB users had significantly higher levels of chloride (105.5 ± 5.8 mEq/L versus 104.1 ± 6.3 mEq/L; p < 0.0001), systolic blood pressure (153.6 ± 24.2 mmHg versus 149.5 ± 25.7 mmHg; p < 0.0016) and CTR (53.9 ± 6.5% versus 54.6 ± 6.5%; p = 0.0376). ARB users had a lower frequency of dialysis-requiring CHF, as compared to ARB non-users (18.5% versus 22.7%; p = 0.0460), despite their higher frequency of diabetic kidney disease, which was usually associated with a higher prevalence of CHF.^{10,11,13,15,16} Among the risk factors for CHF that were confirmed in our multivariate logistic analysis, no significant difference was seen in the frequency of IHD history and serum CRP concentration, between ARB-users and non-users.

Forrest plots of the factors associated with CHF

Figure 3 shows the log-scale Forrest plots for the significant explanatory variables in the multivariate-adjusted logistic regression analysis of risk factors for CHF. Among all CKD medications examined in this study, only ARB use was negatively and independently associated with dialysis-requiring CHF development in the Stage 5 CKD Japanese patients, although ACEI use was not significantly associated. Furthermore, the use of loop diuretics, diabetic kidney disease, a history of IHD, lower levels of serum albumin and hemoglobin, and higher levels of CRP and eGFR, were also independently associated with CHF development.

Figure 3.

Log scale forest plots of the factors associated with CHF in non-dialysis Japanese patients with Stage 5 CKD. Factors significantly associated with CHF after adjusted multivariate analysis are shown.

Discussion

The present multicenter, retrospective, cross-sectional study showed only ARB use was significantly associated with the lower prevalence of dialysis-requiring CHF in non-dialysis Japanese patients with Stage 5 CKD among CKD medications examined in present study. The ARB users had a lower frequency of dialysis-requiring CHF, compared to ARB non-users, despite their higher frequency of diabetic kidney disease, which was usually associated with a higher prevalence of CHF.^{10,11,13,15,16,33} Logistic regression analysis revealed that diabetic kidney disease was also an independent risk factor for CHF, despite its higher comorbidity in the ARB user group. Therefore, we estimated that ARB use may prevent dialysis-requiring CHF in non-dialysis Japanese patients with Stage 5 CKD.

In the present study, ACEI use was not significantly associated with dialysis-requiring CHF. The maximum doses of ACEIs are permitted at a relatively lower range in Japan (enalapril, imidapril, lisinopril, trandolapril, cilazapril and captopril are used at one-quarter to one-half doses) than in Europe and USA, so ACEIs might not fully reduce CHF in Japan. For example, imidapril is used at lower doses, ranging from 2.5–10 mg in Japan, compared to relatively higher doses ranging from 5–20 mg in Europe; and ramipril, an effective ACEI for reduction of cardiovascular events, has not been used in Japan because of it giving persistent cough. Thus, different types and relatively lower doses of ACEIs used in Japan may affect the present consequence (no association between ACEI use and CHF development). Therefore, additional studies are needed to clarify the effect of these drugs on CHF development, in patients with Stage 5 CKD in Japan.

A recent meta-analysis revealed significant reduction of CHF by ACEIs in early-to-moderate CKD patients with diabetes mellitus,¹² but originally published articles^34–41 included in this meta-analysis did not show a significant reduction by ACEIs, except for the HOPE study.⁴¹ This HOPE study evaluated ramipril efficacy on CVD, but ramipril has not been approved in Japan. Thus, the results of the present study (ACEIs have non-significant reduction of CHF) are not inconsistent with previous studies. Though ARBs have been shown to have a significant reduction of CHF in early-to-moderate CKD patients with diabetes mellitus,^42–44 the preventive effect of dialysis-requiring CHF in Stage 5 CKD patients by ARBs has not been reported to date. The present study revealed the possible prevention of dialysis-requiring CHF by ARBs, in CKD Stage 5 Japanese patients.

Unfortunately, the molecular mechanisms responsible for ARB-related prevention of CHF are poorly understood. In the context of tissue protection, blockade of the renin-angiotensin system using ACEIs or ARBs can prevent or reverse endothelial dysfunction and atherosclerosis, thereby reducing the risk of cardiovascular events.⁴⁵ One possible explanation is that angiotensin-II may increase the permeability of the lung vessels,⁴⁶ while another report suggests that angiotensin-II directly induces heart failure in a mouse model of heart failure.⁴⁷ Thus, it is possible that ARB use may reduce the risk of CHF via these mechanisms.

Recently, a large clinical trial involving 20,854 patients revealed the proportion of the patients with CHF at the initiation of dialysis was 19.8%, in Japan.⁴⁸ This prevalence rate was similar to our present data (20.1%); which is a relatively lower frequency, compared to both Canada (31%)⁴⁹ and USA (30.7% in the CKD without diabetes group and 52.3% in the CKD with diabetes group).⁵⁰

There was a significant trend for a stepwise increase in the prevalence of left ventricular ejection fraction (LVEF) to < 55%, corresponding to the advancement in the patients with diabetes kidney disease from CKD Stage 3 to Stage 5.⁵¹ The percentage of LVEF in CKD patients is reported as 69.9 ± 10.4% in Stage 3; 68.2 ± 10.3% in Stage 4; and 67.1 ± 11.0% in Stage 5 pre-dialysis patients (P < 0.05, when compared with Stage 3),⁵² suggesting a stepwise increase in the risk for CHF that corresponds to the stage of advancement of CKD.

Our present study also confirmed that loop diuretic users tended to start dialysis, due to CHF development. In addition, planned dialysis without obvious uremic symptoms was successfully performed more frequently in patients whom did not use loop diuretics (loop diuretics users: 42.39% versus non-users: 57.63%; p < 0.0001). Indeed, the patients with an edematous condition will frequently need loop diuretics to treat the edema and prevent CHF development. Furthermore, there was no significant difference in the use of loop diuretics between ARB users and non-users, suggesting that ARB non-users did not contain the patients with an edematous condition whom easily developed CHF.

In dialysis patients, CHF development is reported to be associated with diabetes mellitus,³³ a history of IHD,⁴⁹ anemia,⁴⁹ hypoalbuminemia,⁴⁹ and higher levels of eGFR^53,54 and CRP.^55–57 Our results also supported that these factors are associated with CHF development in non-dialysis Japanese patients with Stage 5 CKD; however, we did not observe any significant differences regarding the history of IHD, or hemoglobin, eGFR, albumin or CRP levels, when comparing the ARB user and non-user groups. This absence of significant differences supports the conclusion that these factors are independent risk factors for CHF development.

There are several limitations in this study:

The present study used a cross-sectional design, and we do not have any information regarding the types, dosage and duration of each medication;

We had no data from the echocardiography, such as left ventricular ejection fraction;

The low frequency of use for several medications (e.g. ACEI, VDRA, CaCO₃ and AST-120) may have decreased the sensitivity of our statistical analysis; and

Finally, we did not analyze the patients’ lipid profiles or use of statins and other lipid-lowering drugs, as this information was not consistently available.

Conclusion

We found that ARB use during the pre-dialysis period is associated with a lower prevalence of CHF in non-dialysis Japanese patients with Stage 5 CKD, suggesting ARB may provide a possible prevention of dialysis-requiring CHF in non-dialysis Japanese patients with Stage 5 CKD; however, well-controlled prospective studies are needed to confirm our results, given the present study’s cross-sectional design.

Footnotes

Acknowledgements

The authors gratefully acknowledge Hiroyuki Sekihara, Moriaki Osaka, Takashi Watanabe, Hiromi Okamoto, Kazuhiko Kitano and Ryoji Kijima for data collection.

Conflict of interest

The authors declare that there are no conflicts of interest.

Funding statement

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

References

Jha

Garcia-Garcia

Iseki

. Chronic kidney disease: Global dimension and perspectives. Lancet 2013; 382: 260–272.

Matsushita

Van der Velde

Astor

. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: A collaborative meta-analysis. Lancet 2010; 375: 2073–2081.

Chertow

Fan

. Chronic kidney disease and the risks of death, cardiovascular events and hospitalization. N Engl J Med 2004; 351: 1296–1305.

Irie

Iso

Sairenchi

. The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population. Kidney Int 2006; 69: 1264–1271.

Kolesnyk

Struijk

Dekker

. Effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with chronic kidney disease. Neth J Med 2010; 68: 15–23.

Brenner

Cooper

De Zeeuw

. Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861–869.

Lewis

Hunsicker

Clarke

. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. N Engl J Med 2001; 345: 851–860.

Ruggenenti

Perna

Gherardi

. Renoprotective properties of ACE inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999; 354: 359–364.

Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN Group). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 349: 1857–1863.

10.

Balamuthusamy

Srinivasan

Verma

. Renin-angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: A meta-analysis. Am Heart J 2008; 155: 791–805.

11.

The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293–302.

12.

Heran

Wright

. Angiotensin-converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension. Cochrane Database Syst Rev 2014; 8: CD009096. doi: 10.1002/14651858.CD009096.pub2.

13.

Huang

Lin

. Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: Systematic review and Bayesian network meta-analysis. Brit Med J 2013; 347: f6008. doi: 10.1136/bmj.f6008.

14.

Sarafidis

Ruilope

. Aggressive blood pressure reduction and renin-angiotensin system blockade in chronic kidney disease: Time for re-evaluation? Kidney Int 2014; 85: 536–546.

15.

Lang

Struthers

. Targeting the renin-angiotensin-aldosterone system in heart failure. Nat Rev Cardiol 2013; 10: 125–134.

16.

Cheng

Zhang

. Effect of angiotensin-converting enzyme inhibitors and angiotensin-II receptor blockers on all-cause mortality, cardiovascular deaths and cardiovascular events in patients with diabetes mellitus: A meta-analysis. JAMA Intern Med 2014; 174: 773–785.

17.

Israili

Hall

. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy: A review of the literature and pathophysiology. Ann Intern Med 1992; 117: 234–242.

18.

Bangalore

Kumar

Messerli

. Angiotensin-converting enzyme inhibitor associated cough: Deceptive information from the Physicians’ Desk Reference. Am J Med 2010; 123: 1016–1030.

19.

Morimoto

Gandhi

Fiskio

. Development and validation of a clinical prediction rule for angiotensin-converting enzyme inhibitor-induced cough. J Gen Intern Med 2004; 19: 684–691.

20.

Morimoto

Gandhi

Fiskio

. An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors. J Eval Clin Pract 2004; 10: 499–509.

21.

Yeo

Ramsay

. Persistent dry cough with enalapril: Incidence depends on method used. J Hum Hypertens 1990; 4: 517–520.

22.

Woo

Nicholls

. High prevalence of persistent cough with angiotensin-converting enzyme inhibitors in Chinese. Br J Clin Pharmacol 1995; 40: 141–144.

23.

Nishio

Kashiki

Tachibana

. Angiotensin-converting enzyme and bradykinin gene polymorphisms and cough: A meta-analysis. World J Cardiol 2011; 3: 329–336. doi: 10.4330/wjc.v3.i10.329.

24.

Herzog

Asinger

Berger

. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2011; 80: 572–586.

25.

Peters

Kjærgaard

Jespersen

. Renal and cardiovascular effects of irbesartan in dialysis patients: A randomized controlled trial protocol (SAFIR study). Dan Med J 2013; 60: A4602.

26.

Iseki

Arima

Kohagura

. Effects of angiotensin receptor blockade (ARB) on mortality and cardiovascular outcomes in patients with long-term hemodialysis: A randomized controlled trial. Nephrol Dial Transplant 2013; 28: 1579–1589.

27.

Hsu

Liu

Hung

. Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension and anemia. JAMA Intern Med 2014; 174: 347–354.

28.

Zoccali

Torino

Tripepi

. Pulmonary congestion predicts cardiac events and mortality in ESRD. J Am Soc Nephrol 2013; 24: 639–646.

29.

Banerjee

Collins

. Long-term survival of incident hemodialysis patients who are hospitalized for congestive heart failure, pulmonary edema, or fluid overload. Clin J Am Soc Nephrol 2007; 2: 1186–1190.

30.

Matsuo

Imai

Horio

. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982–992.

31.

McKee

Castelli

McNamara

. The natural history of congestive heart failure: The Framingham Study. N Engl J Med 1971; 285: 1441–1446.

32.

Schulman

Berl

Beck

. Randomized Placebo-Controlled EPPIC Trials of AST-120 in CKD. J Am Soc Nephrol. 2014 Oct 27. pii: ASN.2014010042.

33.

Kuwahara

Ishigami

Shikuma

. Type II diabetes mellitus is a risk factor for heart failure in predialysis patients. Ther Apher Dial 2012; 16: 541–547.

34.

Estacio

Jeffers

Hiatt

. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998; 338: 645–652.

35.

Niskanen

Hedner

Hansson

. Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/β-blocker-based treatment regimen: A subanalysis of the Captopril Prevention Project. Diab Care 2001; 24: 2091–2096.

36.

Marre

Lievre

Chatellier

. Effects of low-dose ramipril on cardiovascular and renal outcomes in patients with Type 2 diabetes and raised excretion of urinary albumin: Randomised, double blind, placebo controlled trial (the DIABHYCAR study). Brit Med J 2004; 328: 495–502.

37.

Yui

Sumiyoshi

Kodama

. Nifedipine retard was as effective as angiotensin converting enzyme inhibitors in preventing cardiac events in high-risk hypertensive patients with diabetes and coronary artery disease: The Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) subgroup analysis. Hypertens Res 2004; 27: 449–456.

38.

Daly

Fox

Remme

. The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: Results from the PERSUADE substudy. Eur Heart J 2005; 26: 1369–1378.

39.

Lindholm

Hansson

Ekbom

. Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: Results from the Swedish Trial in Old Patients With Hypertension-2. J Hypertens 2000; 18: 1671–1675.

40.

UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in Type 2 diabetes: UKPDS 39. Brit Med J 1998; 317: 713–720.

41.

Lonn

Yusuf

Hoogwerf

. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253–259.

42.

Lewis

Hunsicker

Clarke

. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. N Engl J Med 2001; 345: 851–860.

43.

Lindholm

Ibsen

Dahlöf

. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): A randomised trial against atenolol. Lancet 2002; 359: 1004–1010.

44.

Brenner

Cooper

De Zeeuw

. Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861–869.

45.

Werner

Baumhäkel

Teo

. RAS blockade with ARB and ACE inhibitors: Current perspective on rationale and patient selection. Clin Res Cardiol 2008; 97: 418–431.

46.

Bodor

Nagy

Végh

. Angiotensin II increases the permeability and PV-1 expression of endothelial cells. Am J Physiol Cell Physiol 2012; 302: C267–276.

47.

Tsukamoto

Mano

Sakata

. A novel heart failure mouse model of hypertensive heart disease by angiotensin-II infusion, nephrectomy and salt loading. Am J Physiol Heart Circ Physiol 2013; 305: H1658–1667.

48.

Yamagata

Nakai

Iseki

. Late dialysis start did not affect long-term outcome in Japanese dialysis patients: Long-term prognosis from Japanese Society for Dialysis Therapy Registry. Ther Apher Dial 2012; 16: 111–120. doi: 10.1111/j.1744–9987.2011.01052.x.

49.

Harnett

Foley

Kent

. Congestive heart failure in dialysis patients: Prevalence, incidence, prognosis and risk factors. Kidney Int 1995; 47: 884–890.

50.

Chen

Chang

Liu

. Stepwise increases in left ventricular mass index and decreases in left ventricular ejection fraction correspond with the stages of chronic kidney disease in diabetes patients. Exp Diabetes Res 2012; 2012: 789325.

51.

Foley

Murray

. Chronic kidney disease and the risk for cardiovascular disease, renal replacement and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 2005; 16: 489–495.

52.

Chen

Hung

. Echocardiographic parameters are independently associated with rate of renal function decline and progression to dialysis in patients with chronic kidney disease. Clin J Am Soc Nephrol 2011; 6: 2750–2758. doi: 10.2215/CJN.04660511.

53.

Crews

Scialla

Liu

. Predialysis health, dialysis timing and outcomes among older US adults. J Am Soc Nephrol 2014; 25: 370–379.

54.

Susantitaphong

Altamimi

Ashkar

. GFR at initiation of dialysis and mortality in CKD: A meta-analysis. Am J Kidney Dis 2012; 59: 829–840.

55.

Vasan

Sullivan

Roubenoff

. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: The Framingham Heart Study. Circulation 2003; 107: 1486–1491.

56.

Suleiman

Khatib

Agmon

. Early inflammation and risk of long-term development of heart failure and mortality in survivors of acute myocardial infarction: Predictive role of C-reactive protein. J Am Coll Cardiol 2006; 47: 962–968.

57.

Gottdiener

Arnold

Aurigemma

. Predictors of congestive heart failure in the elderly: The Cardiovascular Health Study. J Am Coll Cardiol 2000; 35: 1628–1637.

Possible prevention of dialysis-requiring congestive heart failure by angiotensin-II receptor blockers in non-dialysis Japanese patients with Stage 5 chronic kidney disease

Abstract

Background:

Methods:

Results:

Conclusions:

Keywords

Introduction

Methods

Study design

Variables

Statistics

Results

Reasons for starting dialysis

Comparison of patients presenting with or without CHF

Association between various risk factors and the prevalence of CHF

Comparison of patients’ characteristics between ARB users and non-users

Forrest plots of the factors associated with CHF

Discussion

Conclusion

Footnotes

Acknowledgements

Conflict of interest

Funding statement

References